Advertisement | | Open for Submissions
npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.
Explore the benefits of submitting your manuscript. | | | | | |
TABLE OF CONTENTS
| | | | Volume 36, Issue 14 (April 2017) | | In this issue Review Commentary Original Articles Short Communication Oncogenomics
Also new AOP | Advertisement | An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research.
Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions >> | | | | | | | Advertisement | | BIOPHARMA DEALMAKERS - March issue A supplement to Nature Biotechnology | Nature Reviews Drug Discovery Check out the latest issue of BioPharma Dealmakers for the latest dealmaking opportunities, and editorials on personalized cancer vaccines based on tumor-specific neoantigens, the expanding network of microbiome partnerships, and impending growth spurt of the dermatology market. Download the issue for FREE | | | | | | Review | Top | | Translational research in neuroendocrine tumors: pitfalls and opportunitiesJ Capdevila, O Casanovas, R Salazar, D Castellano, A Segura, P Fuster, J Aller, R García-Carbonero, P Jimenez-Fonseca, E Grande and J P Castaño Oncogene 2017 36: 1899-1907; advance online publication, September 19, 2016; 10.1038/onc.2016.316 Abstract | Full Text | | Commentary | Top | | Critical role of the POT1 OB domain in maintaining genomic stabilityT K Pandita Oncogene 2017 36: 1908-1910; advance online publication, November 21, 2016; 10.1038/onc.2016.365 Abstract | Full Text | | Original Articles | Top | | OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumorsL A Jung, A Gebhardt, W Koelmel, C P Ade, S Walz, J Kuper, B von Eyss, S Letschert, C Redel, L d'Artista, A Biankin, L Zender, M Sauer, E Wolf, G Evan, C Kisker and M Eilers Oncogene 2017 36: 1911-1924; advance online publication, October 17, 2016; 10.1038/onc.2016.354 Abstract | Full Text | | | | ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasisD H Peng, C Ungewiss, P Tong, L A Byers, J Wang, J R Canales, P A Villalobos, N Uraoka, B Mino, C Behrens, I I Wistuba, R I Han, C A Wanna, M Fahrenholtz, K J Grande-Allen, C J Creighton and D L Gibbons Oncogene 2017 36: 1925-1938; advance online publication, October 3, 2016; 10.1038/onc.2016.358 Abstract | Full Text | | | | Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesisP Gu, Y Wang, K K Bisht, L Wu, L Kukova, E M Smith, Y Xiao, S M Bailey, M Lei, J Nandakumar and S Chang Oncogene 2017 36: 1939-1951; advance online publication, November 21, 2016; 10.1038/onc.2016.405 Abstract | Full Text | | | | Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1H Liu, H Qiu, Y Song, Y Liu, H Wang, M Lu, M Deng, Y Gu, J Yin, K Luo, Z Zhang, X Jia, G Zheng and Z He Oncogene 2017 36: 1952-1964; advance online publication, October 3, 2016; 10.1038/onc.2016.355 Abstract | Full Text | | | | Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinomaZ Xu, F Yang, D Wei, B Liu, C Chen, Y Bao, Z Wu, D Wu, H Tan, J Li, J Wang, J Liu, S Sun, L Qu and L Wang Oncogene 2017 36: 1965-1977; advance online publication, November 14, 2016; 10.1038/onc.2016.356 Abstract | Full Text | | | | Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injuryP-H Liao, H-H Hsu, T-S Chen, M-C Chen, C-H Day, C-C Tu, Y-M Lin, F-J Tsai, W-W Kuo and C-Y Huang Oncogene 2017 36: 1978-1990; advance online publication, October 17, 2016; 10.1038/onc.2016.357 Abstract | Full Text | | | | Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 inductionT Q Tran, X H Lowman, M A Reid, C Mendez-Dorantes, M Pan, Y Yang and M Kong Oncogene 2017 36: 1991-2001; advance online publication, October 10, 2016; 10.1038/onc.2016.360 Abstract | Full Text | | | | The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage OPENY Xue, A Raharja, W Sim, E S M Wong, S A B Rahmat and D P Lane Oncogene 2017 36: 2002-2013; advance online publication, November 21, 2016; 10.1038/onc.2016.374 Abstract | Full Text | | | | The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cellsS Q Ma, B R Cao, H Zhang, L P Luo, Y Ren, T Hu and C M Chen Oncogene 2017 36: 2014-2022; advance online publication, November 14, 2016; 10.1038/onc.2016.384 Abstract | Full Text | | Short Communication | Top | | An in vivo screening system to identify tumorigenic genesT Ihara, Y Hosokawa, K Kumazawa, K Ishikawa, J Fujimoto, M Yamamoto, T Muramkami, N Goshima, E Ito, S Watanabe and K Semba Oncogene 2017 36: 2023-2029; advance online publication, October 3, 2016; 10.1038/onc.2016.351 Abstract | Full Text | | Oncogenomics | Top | | A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets OPENN A Wijetunga, M Pascual, J Tozour, F Delahaye, M Alani, M Adeyeye, A W Wolkoff, A Verma and J M Greally Oncogene 2017 36: 2030-2044; advance online publication, October 10, 2016; 10.1038/onc.2016.340 Abstract | Full Text | | | | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | | |
No comments:
Post a Comment